Rapport’s Epilepsy Drug Finds Surprising Success in Bipolar Trial

Can This Small Biotech Enter A $4.3 Billion AbbVie Market?

Rapport Therapeutics stock jumped Tuesday on promising, but mixed, test results for its bipolar treatment.

Rapport’s epilepsy drug finds surprising success in bipolar trial

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.

Rapport Therapeutics' RAP-219 Meets Phase 2 Goals in Bipolar Mania Trial

RAP-219 showed a 3.1-point advantage on a mania rating scale after three weeks, but 24.6% of recipients stopped treatment early.

Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study

Rapport Therapeutics said Tuesday its investigational oral drug that dials down the effect of AMPA receptors has cleared a mid-stage trial in bipolar mania, paving the way for registrational studies slated to start next year. ...

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania - PressReach

The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024) RAP-219–treated patients had a 15.4-point mean reduction in YMRS total score from baseline at Week 3 All 11 items measured by the … Continue reading "Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Tr…